Skip to content

Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa

Comparative Efficacy of Nd:YAG and Alexandrite Laser Treatments in Hidradenitis Suppurativa: A Split-Person, Non-Inferiority Study

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06960447
Enrollment
21
Registered
2025-05-07
Start date
2026-01-31
Completion date
2027-07-31
Last updated
2025-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hidradenitis Suppurativa (HS)

Brief summary

The purpose of this study is to evaluate whether Alexandrite laser treatment is non-inferior to Nd:YAG (neodymium-doped yttrium aluminum garnet) laser treatment of hidradenitis suppurativa (HS).

Interventions

Nd:YAG laser applied to one side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.

Alexandrite laser applied to the contralateral side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.

Sponsors

Geisinger Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Split-person trial

Eligibility

Sex/Gender
ALL
Age
12 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Geisinger male or female patients with a diagnosis of hidradenitis suppurativa (all stages of disease) * 12-75 years of age * Not on concurrent systemic therapy (e.g., antibiotics, biologic therapies) * Must have not used systemic therapies within 2 weeks of enrollment in study * Able and willing to provide consent

Exclusion criteria

* Patients who cannot tolerate laser therapy * Patients who cannot wear protective eyewear * Patients who are pregnant

Design outcomes

Primary

MeasureTime frameDescription
HiSCR506 monthsPercentage of patients achieving a 50% reduction in their hidradenitis suppurativa clinical response (HiSCR) score.
HiSQOL6 monthsThe Hidradenitis Suppurativa Quality Of Life (HiSQOL) scale, a validated HS quality of life index and is comprised of a 17-item HS-specific HRQOL instrument with a 7-day recall period. Score ranges from 0 to 68, with higher scores indicating more severe impact

Secondary

MeasureTime frameDescription
Pain VAS score6 monthsVisual analogue score for pain ranging from 0-10 with higher scores indicating worse pain.
Pruritus numeric rating scale6 monthsAs measured by a numeric rating scale from 0-10 with higher scores indicating worse itching.
Days free of disease in last 30 days6 monthsThe number of days a patient has not had a flare of HS in the past 30 days.
AN Count6 monthsNumber of abscesses and nodules on exam

Contacts

Primary ContactSaritha Research Project Manager
skorukonda1@geisinger.edu570-214-3453

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026